{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:24:04Z","timestamp":1789813444419,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00803-y","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:57:19Z","timestamp":1789811839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4477-6255","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Capsius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Pesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-7470","authenticated-orcid":false,"given":"Ravil","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pippig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Hole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-1550","authenticated-orcid":false,"given":"Sigrid","family":"Balser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"22","key":"803_CR1","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","volume":"124","author":"M Weise","year":"2014","unstructured":"Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191\u20136. https:\/\/doi.org\/10.1182\/blood-2014-06-583617.","journal-title":"Blood"},{"key":"803_CR2","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA\/CHMP\/BMWP\/42832\/2005 Rev1). 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf. [Accessed Mar 2026]."},{"key":"803_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.006","author":"MC Bielsky","year":"2020","unstructured":"Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006.","journal-title":"Drug Discov Today"},{"issue":"6","key":"803_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","volume":"37","author":"N Kirsch-Stefan","year":"2023","unstructured":"Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, et al. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855\u201371. https:\/\/doi.org\/10.1007\/s40259-023-00631-4.","journal-title":"BioDrugs"},{"issue":"12","key":"803_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/cpdd.1349","volume":"12","author":"SK Niazi","year":"2023","unstructured":"Niazi SK. Support for removing pharmacodynamic and clinical efficacy testing of Bbosimilars: a critical analysis. Clin Pharmacol Drug Dev. 2023;12(12):1134\u201341. https:\/\/doi.org\/10.1002\/cpdd.1349.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"803_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, et al. The path towards a tailored clinical biosimilar fdevelopment. BioDrugs. 2020;34(3):297\u2013306. https:\/\/doi.org\/10.1007\/s40259-020-00422-1.","journal-title":"BioDrugs"},{"key":"803_CR7","unstructured":"US FDA. Guidance for industry: draft guidance. Scientific considerations in demonstrating biosimilarity to a reference product: updated recommendations for assessing the need for comparative efficacy studies. 2025. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations. [Accessed Feb 2026]."},{"key":"803_CR8","unstructured":"Medicines and Healthcare products Regulatory Agency. Guidance on the licensing of biosimilar products. 2025. Available from: https:\/\/www.gov.uk\/government\/publications\/guidance-on-the-licensing-of-biosimilar-products. [Accessed Mar 2026]."},{"key":"803_CR9","unstructured":"Health Canada. Guidance document: information and submission requirements for biosimilar biologic drugs. 2026. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs.html. [Accessed Jun 2026]."},{"key":"803_CR10","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development (EMA\/CHMP\/BMWP\/60916\/2025). 2026. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf-0. [Accessed Apr 2026]."},{"key":"803_CR11","unstructured":"ICH. ICH Harmonised Guideline M18. Final Concept Paper M18: framework for determining the utility of comparative efficacy studies in biosimilar development programs. 2025. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf. [Accessed Apr 2026]."},{"key":"803_CR12","unstructured":"International Pharmaceutical Regulators Programme (IPRP) Biosimilars Working Group (BWG). Regulatory perspectives on the utility of comparative efficacy studies in biosimilar development programs. 2026. Available from: https:\/\/admin.iprp.global\/sites\/default\/files\/files\/2026-02\/IPRP_BWG_Reg_Perspectives_CES_2026_0220.pdf. [Accessed Apr 2026]."},{"key":"803_CR13","unstructured":"US Food and Drug Administration. FDA takes further steps to streamline biosimilar development and make medicines more affordable. 2026. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable. [Accessed Mar 2026]."},{"issue":"5","key":"803_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-025-02168-y","volume":"85","author":"E Guillen","year":"2025","unstructured":"Guillen E, Barry S, Jost N, Ekman N, Knippel V, Kuhlmann-Gottke J, et al. The tailored biosimilar approach: expectations and requirements. Drugs. 2025;85(5):601\u20138. https:\/\/doi.org\/10.1007\/s40265-025-02168-y.","journal-title":"Drugs"},{"issue":"13","key":"803_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310684","volume":"24","author":"S Wang","year":"2023","unstructured":"Wang S, Khan FI. Investigation of molecular interactions mechanism of pembrolizumab and PD-1. Int J Mol Sci. 2023;24(13):10684. https:\/\/doi.org\/10.3390\/ijms241310684.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"803_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cr.2016.77","volume":"27","author":"Z Na","year":"2017","unstructured":"Na Z, Yeo SP, Bharath SR, Bowler MW, Balikci E, Wang CI, et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017;27(1):147\u201350. https:\/\/doi.org\/10.1038\/cr.2016.77.","journal-title":"Cell Res"},{"issue":"3","key":"803_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40268-024-00485-3","volume":"24","author":"JC St\u00fcber","year":"2024","unstructured":"St\u00fcber JC, Uhland K, Reiter A, Jakob S, Wolschin F. Comparative analytical evaluation of the proposed biosimilar FYB206 and its reference medicinal product Keytruda\u00ae. Drugs R D. 2024;24(3):447\u201364. https:\/\/doi.org\/10.1007\/s40268-024-00485-3.","journal-title":"Drugs R D"},{"key":"803_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106171","volume":"173","author":"M Jaffar-Aghaei","year":"2022","unstructured":"Jaffar-Aghaei M, Khanipour F, Maghsoudi A, Sarvestani R, Mohammadian M, Maleki M, et al. QbD-guided pharmaceutical development of pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda\u00ae. Eur J Pharm Sci. 2022;173:106171. https:\/\/doi.org\/10.1016\/j.ejps.2022.106171.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"803_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49\u201357. https:\/\/doi.org\/10.1002\/psp4.12139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"803_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12132","volume":"6","author":"J Elassaiss-Schaap","year":"2017","unstructured":"Elassaiss-Schaap J, Rossenu S, Lindauer A, Kang SP, de Greef R, Sachs JR, et al. Using model-based \u201clearn and confirm\u201d to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):21\u20138. https:\/\/doi.org\/10.1002\/psp4.12132.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","volume":"5","author":"T Freshwater","year":"2017","unstructured":"Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017;5:43. https:\/\/doi.org\/10.1186\/s40425-017-0242-5.","journal-title":"J Immunother Cancer"},{"key":"803_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113530","volume":"199","author":"JR Brahmer","year":"2024","unstructured":"Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024;199:113530. https:\/\/doi.org\/10.1016\/j.ejca.2024.113530.","journal-title":"Eur J Cancer"},{"key":"803_CR23","unstructured":"Formycon AG. Formycon announces positive clinical data for Keytruda\u00ae biosimilar candidate FYB206 (pembrolizumab). Press Release, 25 Feb 2026. Available from: https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-positive-clinical-data-for-keytruda-biosimilar-candidate-fyb206-pembrolizumab\/. [Accessed Mar 2026]."},{"issue":"4","key":"803_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jcph.6165","volume":"65","author":"P Ji","year":"2025","unstructured":"Ji P, Schrieber SJ, Glaser R, Chen J, Shukla C, Doddapaneni S, et al. A meta-analysis of the safety and immunogenicity of pharmacokinetic similarity studies and comparative clinical studies. J Clin Pharmacol. 2025;65(4):499\u2013507. https:\/\/doi.org\/10.1002\/jcph.6165.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"803_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-025-00733-1","volume":"39","author":"M Schiestl","year":"2025","unstructured":"Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, et al. Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: an ustekinumab case study. BioDrugs. 2025;39(5):769\u201376. https:\/\/doi.org\/10.1007\/s40259-025-00733-1.","journal-title":"BioDrugs"},{"key":"803_CR26","unstructured":"Center for Drug Evaluation and Research. Application Number 125514Orig1s000. Clinical pharmacology and biopharmaceutics review(s): Keytruda. 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125514Orig1s000ClinPharmR.pdf. [Accessed Feb 2026]."},{"key":"803_CR27","unstructured":"Formycon AG. Formycon announces decision on phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201. Press Release, 17 Feb 2025. Available from: https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-decision-on-phase-iii-trial-with-fyb206-and-provides-update-on-potential-need-to-adjust-the-valuation-of-fyb202-and-fyb201\/. [Accessed Mar 2026]."},{"key":"803_CR28","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (EMA\/CHMP\/BWP\/247713\/2012). 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-revision-1_en.pdf. [Accessed Feb 2026]."},{"key":"803_CR29","unstructured":"US Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2016. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product. [Accessed Feb 2026]."},{"issue":"1","key":"803_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108\u201323. https:\/\/doi.org\/10.1002\/cpt.2785.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"803_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85329-9","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Zhao R, Chen J, Tian W, Xia C, Liu X, et al. Next generation of anti-PD-L1 atezolizumab with enhanced anti-tumor efficacy in vivo. Sci Rep. 2021;11(1):5774. https:\/\/doi.org\/10.1038\/s41598-021-85329-9.","journal-title":"Sci Rep"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00803-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00803-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00803-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:57:27Z","timestamp":1789811847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00803-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":31,"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00803-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"26 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that generative AI was used in the creation of this article. Generative AI was used to suggest rephrasing of individual paragraphs and to support literature discovery. All content was reviewed and edited by the authors, who take full responsibility for the article.","order":1,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bj\u00f6rn Capsius, Marija Pesic, Ravil Niyazov, Susanne Pippig, Michael Trieb, Rahul Hole, Sigrid Balser, and Andreas Seidl are employed by Formycon AG, which is developing biosimilar medicines.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No patient data were accessed; therefore, no ethical review board review was required.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BC and AS developed the concept. SB and MT gave conceptual support. BC and MP wrote the manuscript. RN, SP, MT, RH, SB, and AS reviewed the manuscript. BC and MP revised the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}